Anbarasu Kumaraswamy1, Katherine R Welker Leng1, Thomas C Westbrook1, Joel A Yates1, Shuang G Zhao2, Christopher P Evans3, Felix Y Feng4, Todd M Morgan1, Joshi J Alumkal5. 1. Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. 2. Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 3. Department of Urologic Surgery and UC Davis Cancer Center, University of California Davis, Sacramento, CA, USA. 4. Department of Radiation Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. 5. Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. Electronic address: jalumkal@med.umich.edu.
Abstract
CONTEXT: In addition to genetic alterations, epigenetic alterations play a crucial role during prostate cancer progression. A better understanding of the epigenetic factors that promote prostate cancer progression may lead to the design of rational therapeutic strategies to target prostate cancer more effectively. OBJECTIVE: To systematically review recent literature on the role of epigenetic factors in prostate cancer and highlight key preclinical and translational data with epigenetic therapies. EVIDENCE ACQUISITION: We performed a systemic literature search in PubMed. At the request of the editors, we limited our search to articles published between January 2015 and August 2020 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Clinical trials targeting epigenetic factors were retrieved from clinicaltrials.gov. EVIDENCE SYNTHESIS: We retrieved 1451 articles, and 62 were finally selected for review. Twelve additional foundational studies outside this time frame were also included. Findings from both preclinical and clinical studies were reviewed and summarized. We also discuss 12 ongoing clinical studies with epigenetic targeted therapies. CONCLUSIONS: Epigenetic mechanisms impact prostate cancer progression. Understanding the role of specific epigenetic factors is critical to determine how we may improve prostate cancer treatment and modulate resistance to standard therapies. Recent preclinical studies and ongoing or completed clinical studies with epigenetic therapies provide a useful roadmap for how to best deploy epigenetic therapies clinically to target prostate cancer. PATIENT SUMMARY: Epigenetics is a process by which gene expression is regulated without changes in the DNA sequence itself. Oftentimes, epigenetic changes influence cellular behavior and contribute to cancer development or progression. Understanding how epigenetic changes occur in prostate cancer is the first step toward therapeutic targeting in patients. Importantly, laboratory-based studies and recently completed and ongoing clinical trials suggest that drugs targeting epigenetic factors are promising. More work is necessary to determine whether this class of drugs will add to our existing treatment arsenal in prostate cancer.
CONTEXT: In addition to genetic alterations, epigenetic alterations play a crucial role during prostate cancer progression. A better understanding of the epigenetic factors that promote prostate cancer progression may lead to the design of rational therapeutic strategies to target prostate cancer more effectively. OBJECTIVE: To systematically review recent literature on the role of epigenetic factors in prostate cancer and highlight key preclinical and translational data with epigenetic therapies. EVIDENCE ACQUISITION: We performed a systemic literature search in PubMed. At the request of the editors, we limited our search to articles published between January 2015 and August 2020 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Clinical trials targeting epigenetic factors were retrieved from clinicaltrials.gov. EVIDENCE SYNTHESIS: We retrieved 1451 articles, and 62 were finally selected for review. Twelve additional foundational studies outside this time frame were also included. Findings from both preclinical and clinical studies were reviewed and summarized. We also discuss 12 ongoing clinical studies with epigenetic targeted therapies. CONCLUSIONS: Epigenetic mechanisms impact prostate cancer progression. Understanding the role of specific epigenetic factors is critical to determine how we may improve prostate cancer treatment and modulate resistance to standard therapies. Recent preclinical studies and ongoing or completed clinical studies with epigenetic therapies provide a useful roadmap for how to best deploy epigenetic therapies clinically to target prostate cancer. PATIENT SUMMARY: Epigenetics is a process by which gene expression is regulated without changes in the DNA sequence itself. Oftentimes, epigenetic changes influence cellular behavior and contribute to cancer development or progression. Understanding how epigenetic changes occur in prostate cancer is the first step toward therapeutic targeting in patients. Importantly, laboratory-based studies and recently completed and ongoing clinical trials suggest that drugs targeting epigenetic factors are promising. More work is necessary to determine whether this class of drugs will add to our existing treatment arsenal in prostate cancer.
Authors: Michael A Augello; Deli Liu; Lesa D Deonarine; Brian D Robinson; Dennis Huang; Suzan Stelloo; Mirjam Blattner; Ashley S Doane; Elissa W P Wong; Yu Chen; Mark A Rubin; Himisha Beltran; Olivier Elemento; Andries M Bergman; Wilbert Zwart; Andrea Sboner; Noah Dephoure; Christopher E Barbieri Journal: Cancer Cell Date: 2019-03-28 Impact factor: 31.743
Authors: Lingling Duan; Ganesha Rai; Carlos Roggero; Qing-Jun Zhang; Qun Wei; Shi Hong Ma; Yunyun Zhou; John Santoyo; Elisabeth D Martinez; Guanghua Xiao; Ganesh V Raj; Ajit Jadhav; Anton Simeonov; David J Maloney; Josep Rizo; Jer-Tsong Hsieh; Zhi-Ping Liu Journal: Chem Biol Date: 2015-09-10
Authors: Alfonso Urbanucci; Stefan J Barfeld; Ville Kytölä; Harri M Itkonen; Ilsa M Coleman; Daniel Vodák; Liisa Sjöblom; Xia Sheng; Teemu Tolonen; Sarah Minner; Christoph Burdelski; Kati K Kivinummi; Annika Kohvakka; Steven Kregel; Mandeep Takhar; Mohammed Alshalalfa; Elai Davicioni; Nicholas Erho; Paul Lloyd; R Jeffrey Karnes; Ashley E Ross; Edward M Schaeffer; Donald J Vander Griend; Stefan Knapp; Eva Corey; Felix Y Feng; Peter S Nelson; Fahri Saatcioglu; Karen E Knudsen; Teuvo L J Tammela; Guido Sauter; Thorsten Schlomm; Matti Nykter; Tapio Visakorpi; Ian G Mills Journal: Cell Rep Date: 2017-06-06 Impact factor: 9.423
Authors: M L Nickerson; S Das; K M Im; S Turan; S I Berndt; H Li; H Lou; S A Brodie; J N Billaud; T Zhang; A J Bouk; D Butcher; Z Wang; L Sun; K Misner; W Tan; A Esnakula; D Esposito; W Y Huang; R N Hoover; M A Tucker; J R Keller; J Boland; K Brown; S K Anderson; L E Moore; W B Isaacs; S J Chanock; M Yeager; M Dean; T Andresson Journal: Oncogene Date: 2016-11-07 Impact factor: 9.867
Authors: Daniel J Coleman; Lina Gao; Jacob Schwartzman; James E Korkola; David Sampson; Daniel S Derrick; Joshua Urrutia; Ariel Balter; Julja Burchard; Carly J King; Kami E Chiotti; Laura M Heiser; Joshi J Alumkal Journal: Sci Rep Date: 2019-03-07 Impact factor: 4.379
Authors: Zeda Zhang; Chuanli Zhou; Xiaoling Li; Spencer D Barnes; Su Deng; Elizabeth Hoover; Chi-Chao Chen; Young Sun Lee; Yanxiao Zhang; Choushi Wang; Lauren A Metang; Chao Wu; Carla Rodriguez Tirado; Nickolas A Johnson; John Wongvipat; Kristina Navrazhina; Zhen Cao; Danielle Choi; Chun-Hao Huang; Eliot Linton; Xiaoping Chen; Yupu Liang; Christopher E Mason; Elisa de Stanchina; Wassim Abida; Amaia Lujambio; Sheng Li; Scott W Lowe; Joshua T Mendell; Venkat S Malladi; Charles L Sawyers; Ping Mu Journal: Cancer Cell Date: 2020-03-26 Impact factor: 31.743
Authors: Xiangyi Li; GuemHee Baek; Suzanne Carreira; Wei Yuan; Shihong Ma; Mia Hofstad; Sora Lee; Yunpeng Gao; Claudia Bertan; Maria de Los Dolores Fenor de la Maza; Prasanna G Alluri; Sandeep Burma; Benjamin Pc Chen; Ganesh V Raj; Johann de Bono; Yves Pommier; Ram S Mani Journal: JCI Insight Date: 2022-05-09